Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2576-2607
Closed Access | Times Cited: 131

Showing 1-25 of 131 citing articles:

PROTAC targeted protein degraders: the past is prologue
Miklós Békés, David R. Langley, Craig M. Crews
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 3, pp. 181-200
Open Access | Times Cited: 1651
PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 376
Cancer Selective Target Degradation by Folate-Caged PROTACs
Jing Liu, He Chen, Yi Liu, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 19, pp. 7380-7387
Open Access | Times Cited: 187
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
Shipeng He, Fei Gao, Junhui Ma, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 43, pp. 23299-23305
Closed Access | Times Cited: 173
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 151
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 148
Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 122
Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation
Yu Chen, Ira Tandon, William J. Heelan, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 13, pp. 5330-5350
Open Access | Times Cited: 120
Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 116
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S. Dragovich, Thomas H. Pillow, Robert A. Blake, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2534-2575
Closed Access | Times Cited: 113
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 112
Payload diversification: a key step in the development of antibody–drug conjugates
Louise Conilh, Lenka Sadílková, Warren Viricel, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Degrader-antibody conjugates
Peter S. Dragovich
Chemical Society Reviews (2022) Vol. 51, Iss. 10, pp. 3886-3897
Closed Access | Times Cited: 76
Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory
Angus D. Cowan, Alessio Ciulli
Annual Review of Biochemistry (2022) Vol. 91, Iss. 1, pp. 295-319
Open Access | Times Cited: 72
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 69
Delivering on the promise of protein degraders
Matthew N. O’Brien, Suman Luthra, Matthew F. Brown, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 5, pp. 410-427
Closed Access | Times Cited: 48
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 45
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 42
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 38
Targeting cancer with small-molecule pan-KRAS degraders
Johannes Popow, William Farnaby, Andreas Gollner, et al.
Science (2024) Vol. 385, Iss. 6715, pp. 1338-1347
Open Access | Times Cited: 21
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 13
Integrative Modeling of PROTAC-Mediated Ternary Complexes
Gaoqi Weng, Dan Li, Yu Kang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 21, pp. 16271-16281
Closed Access | Times Cited: 78
Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
Lin Zhang, Ling Li, Xia Wang, et al.
Molecular Therapy — Nucleic Acids (2022) Vol. 30, pp. 66-79
Open Access | Times Cited: 61
Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras
He Chen, Jing Liu, H. Ümit Kanıskan, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 12273-12285
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top